Differential impact of fibroblasts on the efficient cell death of lung cancer cells induced by paclitaxel and cisplatin

Cancer Biology and Therapy

Volumn 7, Issue 8, 2008, Pages 1250-1261

  Bartling, Babett ^a   Hofmann, Hans Stefan ^b   Silber, Rolf Edgar ^a   Simm, Andreas ^a  

^a MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^b Hospital Barmherzige Bruder Regensburg   (Germany)

Author keywords

Apoptosis; Carcinoma; Cisplatin; Fibroblasts; Lung; Necrosis; Paclitaxel

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; APOPTOSIS INDUCING FACTOR; BIM PROTEIN; CASPASE 3; CASPASE 7; CASPASE 9; CISPLATIN; CYTOCHROME C; ETOPOSIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PACLITAXEL; PROTEIN BCL 2; PROTEIN KINASE B; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL DEATH; CELL NUCLEUS; CELL VIABILITY; COCULTURE; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LUNG FIBROBLAST; LUNG NON SMALL CELL CANCER; MITOCHONDRION; PARACRINE SIGNALING; PROTEIN PHOSPHORYLATION;

EID: 49749115740     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.8.6264     Document Type: Article

References (54)

1. Cersosimo RJ. Lung cancer: a review. Am J Health Syst Pharm 2002; 59:611-42.
2. Volm M, Rittgen W. Cellular predictive factors for the drug response of lung cancer. Anticancer Res 2000; 20:3449-58.
3. Park CC, Bissell MJ, Barcellos-Hoff MH. The influence of the microenvironment on the malignant phenotype. Mol Med Today 2000; 6:324-9.
4. Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004; 4:839-49.
5. Kiaris H, Chatzistamou I, Kalofoutis C, Koutselini H, Piperi C, Kalofoutis A. Tumour-stroma interactions in carcinogenesis: basic aspects and perspectives. Mol Cell Biochem 2004; 261:117-22.
6. Kunz-Schughart LA, Knuechel R. Tumor-associated fibroblasts (part I): Active stromal participants in tumor development and progression? Histol Histopathol 2002; 17:599-621.
7. Kunz-Schughart LA, Knuechel R. Tumor-associated fibroblasts (part II): Functional impact on tumor tissue. Histol Histopathol 2002; 17:623-37.
8. Micke P, Ostman A. Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer 2004; 45:163-75.
9. Beacham DA, Cukierman E. Stromagenesis: the changing face of fibroblastic microenvironments during tumor progression. Semin Cancer Biol 2005; 15:329-41.
10. Bartling B, Demling N, Silber RE, Simm A. Proliferative stimulus of lung fibroblasts on lung cancer cells is impaired by RAGE. Am J Respir Cell Mol Biol 2006; 34:83-91.
11. Cekanova M, Masi T, Plummer HK, Majidi M, Fedorocko P, Schuller HM. Pulmonary fibroblasts stimulate the proliferation of cell lines from human lung adenocarcinomas. Anticancer Drugs 2006; 17:771-81.
12. Wernert N. The multiple roles of tumour stroma. Virchows Arch 1997; 430:433-43.
13. Bartling B, Rehbein G, Silber RE, Simm A. Senescent fibroblasts induce moderate stress in lung epithelial cells in vitro. Exp Gerontol 2006; 41:532-9.
14. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res 1998; 74:49-139.
15. Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci USA 2001; 98:9666-70.
16. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91:231-41.
17. Thomas G. The S6 kinase signaling pathway in the control of development and growth. Biol Res 2002; 35:305-13.
18. Muerkoster S, Wegehenkel K, Arlt A, Witt M, Sipos B, Kruse ML, Sebens T, Kloppel G, Kalthoff H, Folsch UR, Schafer H. Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res 2004; 64:1331-7.
19. Miyake H, Hara I, Gohji K, Yoshimura K, Arakawa S, Kamidono S. Expression of basic fibroblast growth factor is associated with resistance to cisplatin in a human bladder cancer cell line. Cancer Lett 1998; 123:121-6.
20. 2 delay and a hyperphosphorylation of p34CDC2 in HeLa cells. Cancer Res 1997; 57:1364-70.
21. Song S, Wientjes MG, Gan Y, Au JL. Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci USA 2000; 97:8658-63.
22. Konig A, Menzel T, Lynen S, Wrazel L, Rosen A, Al-Katib A, Raveche E, Gabrilove JL. Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia 1997; 11:258-65.
23. Hauptmann S, Siegert A, Berger S, Denkert C, Kobel M, Ott S, Siri A, Borsi L. Regulation of cell growth and the expression of extracellular matrix proteins in colorectal adenocarcinoma: a fibroblast-tumor cell coculture model to study tumor-host interactions in vitro. Eur J Cell Biol 2003; 82:1-8.
24. Fromigue O, Louis K, Dayem M, Milanini J, Pages G, Tartare-Deckert S, Ponzio G, Hofman P, Barbry P, Auberger P, Mari B. Gene expression profiling of normal human pulmonary fibroblasts following coculture with non-small-cell lung cancer cells reveals alterations related to matrix degradation, angiogenesis, cell growth and survival. Oncogene 2003; 22:8487-97.
25. Qian LW, Mizumoto K, Maehara N, Ohuchida K, Inadome N, Saimura M, Nagai E, Matsumoto K, Nakamura T, Tanaka M. Co-cultivation of pancreatic cancer cells with orthotopic tumor-derived fibroblasts: fibroblasts stimulate tumor cell invasion via HGF secretion whereas cancer cells exert a minor regulative effect on fibroblasts HGF production. Cancer Lett 2003; 190:105-12.
26. Murren JR. Rationale for non-platinum chemotherapy in advanced NSCLC. Oncology (Williston Park) 2001; 15:29-34.
27. Schiller JH. Current standards of care in small-cell and non-small-cell lung cancer. Oncology 2001; 61:3-13.
28. Takahashi T, Carbone D, Nau MM, Hida T, Linnoila I, Ueda R, Minna JD. Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res 1992; 52:2340-3.
29. Chen JY, Funk WD, Wright WE, Shay JW, Minna JD. Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences. Oncogene 1993; 8:2159-66.
30. Bartling B, Lewensohn R, Zhivotovsky B. Endogenously released Smac is insufficient to mediate cell death of human lung carcinoma in response to etoposide. Exp Cell Res 2004; 298:83-95.
31. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996; 56:816-25.
32. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP, Wang X. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997; 275:1129-32.
33. van Loo G, Saelens X, van Gurp M, MacFarlane M, Martin SJ, Vandenabeele P. The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet. Cell Death Differ 2002; 9:1031-42.
34. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91:479-89.
35. Susin SA, Daugas E, Ravagnan L, Samejima K, Zamzami N, Loeffler M, Costantini P, Ferri KF, Irinopoulou T, Prevost MC, Brothers G, Mak TW, Penninger J, Earnshaw WC, Kroemer G. Two Distinct Pathways Leading to Nuclear Apoptosis. J Exp Med 2000; 192:571-80.
36. Mollinedo F, Gajate C. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 2003; 8:413-50.
37. 1 checkpoint response in mouse embryo fibroblasts depends on the specific DNA damage inducer. Oncogene 2004; 23:973-80.
38. Sorenson CM, Eastman A. Influence of cis-diamminedichloroplatinum(II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. Cancer Res 1988; 48:6703-7.
39. Fenig E, Livnat T, Sharkon-Polak S, Wasserman L, Beery E, Lilling G, Yahalom J, Wieder R, Nordenberg J. Basic fibroblast growth factor potentiates cisplatinum-induced cytotoxicity in MCF-7 human breast cancer cells. J Cancer Res Clin Oncol 1999; 125:556-62.
40. Hilger RA, Scheulen ME, Strumberg D. The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie 2002; 25:511-8.
41. Okano J, Rustgi AK. Paclitaxel induces prolonged activation of the Ras/MEK/ERK pathway independently of activating the programmed cell death machinery. J Biol Chem 2001; 276:19555-64.
42. MacKeigan JP, Collins TS, Ting JP. MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem 2000; 275:38953-6.
43. McDaid HM, Horwitz SB. Selective potentiation of paclitaxel (taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines. Mol Pharmacol 2001; 60:290-301.
44. McDaid HM, Lopez-Barcons L, Grossman A, Lia M, Keller S, Perez-Soler R, Horwitz SB. Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants. Cancer Res 2005; 65:2854-60.
45. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998; 282:1318-21.
46. Puthalakath H, Huang DC, O'Reilly LA, King SM, Strasser A. The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol Cell 1999; 3:287-96.
47. Li Z, Zhang J, Liu Z, Woo CW, Thiele CJ. Downregulation of Bim by brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from paclitaxel but not etoposide or cisplatin-induced cell death. Cell Death Differ 2007; 14:318-26.
48. Debernardis D, Sire EG, De Feudis P, Vikhanskaya F, Valenti M, Russo P, Parodi S, D'Incalci M, Broggini M. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res 1997; 57:870-4.
49. Sirzen F, Zhivotovsky B, Nilsson A, Bergh J, Lewensohn R. Higher spontaneous apoptotic index in small cell compared with non-small cell lung carcinoma cell lines; lack of correlation with Bcl-2/Bax. Lung Cancer 1998; 22:1-13.
50. Han JY, Chung YJ, Park SW, Kim JS, Rhyu MG, Kim HK, Lee KS. The relationship between cisplatin-induced apoptosis and p53, bcl-2 and bax expression in human lung cancer cells. Korean J Intern Med 1999; 14:42-52.
51. Joseph B, Ekedahl J, Sirzen F, Lewensohn R, Zhivotovsky B. Differences in expression of pro-caspases in small cell and non-small cell lung carcinoma. Biochem Biophys Res Commun 1999; 262:381-7.
52. Porebska I, Wyrodek E, Kosacka M, Adamiak J, Jankowska R, Harlozinska-Szmyrka A. Apoptotic markers p53, Bcl-2 and Bax in primary lung cancer. In Vivo 2006; 20:599-604.
53. Huisman C, Ferreira CG, Broker LE, Rodriguez JA, Smit EF, Postmus PE, Kruyt FA, Giaccone G. Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460. Clin Cancer Res 2002; 8:596-606.
54. Joseph B, Marchetti P, Formstecher P, Kroemer G, Lewensohn R, Zhivotovsky B. Mitochondrial dysfunction is an essential step for killing of non-small cell lung carcinomas resistant to conventional treatment. Oncogene 2002; 21:65-77.